Subject: To participate in a cross-sectional survey on Demographics & Management Practices in Erosive Esophagitis
Esophagitis refers to inflammation or injury to the esophageal mucosa. There are many causes of esophagitis and essentially the presentation is similar which include retrosternal chest, heartburn, dysphagia or odynophagia. One of the most common causes is gastroesophageal reflux, which can lead to erosive esophagitis.
The most common symptoms in patients with esophagitis are chest pain, odynophagia, and dysphagia. If the esophagitis is severe and leads to strictures, fistulization, and perforation, patients may present with symptoms related to those entities. Acid-related disorders influence the quality of life and productivity of afflicted patients and are common and important causes of morbidity and mortality.
About 10% of GERD patients in India have erosive esophagitis. Due to its long-term morbidity, it is crucial to identify risk factors that contribute to the development of EE to decide the need for endoscopy and/or histopathology analysis, to detect an early mucosal erosion, and to prevent its progression to Barret’s Esophagus (BE) and esophageal adenocarcinoma. The severity of EE is commonly graded using the Los Angeles (LA) classification system as grade A (minimal) to D (very severe), depending on the extent of endoscopically visible mucosal breaks. Accurate grading of EE severity is crucial as EE severity strongly influences both initial rates of healing and the likelihood of recurrence during maintenance treatment.
Potassium-competitive acid blockers (PCABs) represent a novel class of acid suppressants that have shown tremendous promise to enhance the care of acid peptic disorders. PCABs' characteristics are distinct from those of proton pump inhibitors, such as acid stability with dosing independent of food consumption, rapid onset of action, less variability with CYP2C19 polymorphisms, and extended half-lives. PCABs now have data beyond Asian populations and expanding regulatory approvals.
This survey will help:
• To understand prevalence and profile of patients with erosive esophagitis in India
• To understand the diagnostic practices for Erosive Esophagitis in India
• To understand the treatment approach by Indian healthcare professionals for Erosive Esophagitis
If you agree to participate, you must provide an assessment response to the standard questionnaire form. A link will be provided for the same on your registered email address.
We trust you, and we are partners in safe and effective drug therapy. In that spirit, we hope you will consent to participate in this survey.
|
}}){kind=logo}
}})